Need help choosing the right code?
Ask CasePilot about procedures, modifiers, bundling, and coding guidance.
Try CasePilot© Copyright 2026 American Medical Association. All rights reserved.
The CPT® Code 86409 refers to a laboratory test that measures the presence and activity of neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for coronavirus disease (COVID-19). This test is particularly significant in evaluating a person's immune response following infection with the virus or after vaccination. It is commonly utilized to assess the eligibility of plasma donors who have recovered from COVID-19, as their plasma may contain antibodies that can be beneficial for treating patients currently infected with the virus. The neutralizing antibody test specifically quantifies the ability of these antibodies to inhibit the virus's ability to infect cells, providing insight into the level of protection an individual may have against future infections or reinfections. The process involves mixing blood serum or plasma with target cells and a synthetic virus that expresses the spike protein of SARS-CoV-2. By performing serial dilutions and measuring the luminescent signal generated in response to viral infection, healthcare professionals can determine the titer, or concentration, of neutralizing antibodies present in the sample. This information is crucial for understanding an individual's immune status and potential protection against COVID-19.
© Copyright 2026 Coding Ahead. All rights reserved.
The neutralizing antibody test (CPT® Code 86409) is indicated for several specific purposes related to the assessment of immune response to SARS-CoV-2. These indications include:
The procedure for conducting the neutralizing antibody test involves several critical steps to ensure accurate measurement of antibody activity. These steps include:
Post-procedure care for patients undergoing the neutralizing antibody test is generally minimal, as the test primarily involves laboratory analysis of blood samples. However, it is important to monitor patients for any potential adverse reactions related to blood collection, such as bruising or discomfort at the venipuncture site. Results from the test may take some time to process, and healthcare providers should communicate the findings to the patient, discussing the implications of the antibody titer in relation to their immune status and potential protection against COVID-19. Follow-up consultations may be necessary to address any questions or concerns regarding the results and subsequent health decisions.
| Short Descr | NEUTRLZG ANTB SARSCOV2 TITER | Medium Descr | NEUTRALIZING ANTIBODY SARS-COV-2 TITER | Long Descr | Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]); titer | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | CLIA Waived (QW) | No | APC Status Indicator | Service Paid under Fee Schedule or Payment System other than OPPS | Type of Service (TOS) | 5 - Diagnostic Laboratory | Berenson-Eggers TOS (BETOS) | none | MUE | 1 |
| 90 | Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number. | 59 | Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25. | Q1 | Routine clinical service provided in a clinical research study that is in an approved clinical research study | GW | Service not related to the hospice patient's terminal condition | GV | Attending physician not employed or paid under arrangement by the patient's hospice provider | XU | Unusual non-overlapping service, the use of a service that is distinct because it does not overlap usual components of the main service |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2023-01-01 | Note | Grammar correction |
| 2022-01-01 | Added | First appearance in code book |
| 2022-01-01 | Changed | Code description changed. |
| 2021-01-01 | Added | First appearance of code in CPT® Code Set. |
| 2020-08-10 | Added | Code added. |
Get instant expert-level medical coding assistance.